KRT17 antibody

Catalog No. ABIN2742462

This anti-KRT17 antibody is a Mouse Monoclonal antibody detecting KRT17 in WB, IHC, IF, ELISA, FACS, IP and IHC (p). Suitable for Human, Rat, Cow, Pig and Goat.

Quick Overview for KRT17 antibody (ABIN2742462)

Target: KRT17 (Keratin 17 (KRT17))

Reactivity: Human, Rat, Cow, Pig, Goat

Host: Mouse

Clonality: Monoclonal

Conjugate: This KRT17 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), ELISA, Flow Cytometry (FACS), Immunoprecipitation (IP), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: E3

Product Details anti-KRT17 Antibody

Specificity: KRT17 / CK17 / Cytokeratin 17

Purification: Protein G purified

Immunogen: The cytoskeletal fraction of rat colon epithelium.

Type of Immunogen: Cell fraction

Isotype: IgG2b kappa

Application Details

Application Notes: Approved: ELISA, Flo (0.5 - 1 μg/10 x10⁶), IF (1 - 2 μg/mL), IHC, IHC-P (0.5 - 1 μg/mL), IP, WB (0.5 - 1 μg/mL)

Usage: Cytokeratin 17 (CK17, Keratin 17) is a member of the Cytokeratin subfamily of intermediate filament proteins (IFP's). It is unique in that it is normally expressed in the basal cells of complex epithelia but not in stratified or simple epithelia. Cytokeratin 17 is expressed in the nail bed, hair follicle, sebaceous glands and other epidermal appendages. Antibody to cytokeratin 17 is an excellent tool to distinguish myoepithelial cells from luminal epithelium of various glands such as mammary, sweat and salivary. It is expressed in epithelial cells of various origins, such as bronchial epithelial cells and skin appendages. It may be considered as [Character 93]epithelial stem cell[Character 94] marker because cytokeratin 17 antibody marks basal cell differentiation. Cytokeratin 17 can be useful when included in a panel of antibodies against TTF-1, napsin A, CK5&6, p63, and SOX-2 for diagnostic differentiation between lung adenocarcinoma (LADC) and lung squamous cell carcinoma (SCLC), especially for poorly-differentiated lung carcinoma. Cytokeratin 17 is expressed in SCLC much higher than in LADC. In breast carcinomas, approximately 20 % of patients show no expression of ER, PR and Her2, which are defined as triple negative tumor. Eighty-five percent of the triple negative breast carcinomas immunoreact with basal cytokeratins including cytokeratin 17 antibody. Also important is that cases of triple negative breast carcinoma with expression of keratin 17 show an aggressive clinical course. The histologic differentiation of ampullary cancer, intestinal vs. pancreatobiliary, is very important for treatment. Usually antibody to cytokeratin 17 and MUC1 immunoreactivity represents pancreatobiliary subtype whereas antibody to MUC2 and CDX2 positivity defines intestinal subtype. ELISA: Order BSA-free format for coating.

Comment:

Target Species of Antibody: Rat

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: Lot specific

Buffer: PBS,  pH 7.4, 0.1 mg/mL BSA, 0.05 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Store at 2°C to 8°C.

Target Details for KRT17

Target: KRT17 (Keratin 17 (KRT17))

Alternative Name: KRT17 / CK17 / Cytokeratin 17

Background: Name/Gene ID: KRT17
Family: Keratin

Synonyms: KRT17, 39.1, Cytokeratin 17, Cytokeratin-17, K17, Keratin 17 epitope S2, Keratin 17 epitope S4, Keratin 17, PC2, PCHC1, CK-17, Keratin 17 epitope S1, Keratin-17

Gene ID: 3872